Log In
BCIQ
Print this Print this
 

MC-1101, SB04

  Manage Alerts
Collapse Summary General Information
Company MacuClear Inc.
DescriptionTopically administered eye drop that restores choroidal blood flow
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II/III
Standard IndicationAge-related macular degeneration (AMD)
Indication DetailsTreat age-related macular degeneration (AMD); Treat dry age-related macular degeneration (AMD)
Regulatory Designation U.S. - Fast Track (Treat age-related macular degeneration (AMD))
PartnerSynCore Biotechnology Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/09/2012

Undisclosed

Undisclosed

Undisclosed

05/17/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today